• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments

by Bellbrook Labs / Monday, 17 May 2021 / Published in Company, Emerging Targets
TREX1 Inhibitor Assays

TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or malfunctioning patient cells. The innate immune response relies on various cell types and proteins such as interferons (INFs) to be successful. There are three types of cytokines within this group, all of which aid in removing viral pathogens. When interferon regulatory factor 3 (IRF3) is activated, type I interferon is produced, which has an antiviral effect.¹ However, in the case of human immunodeficiency virus (HIV), three prime repair exonuclease I (TREX1) blocks antiviral activity. Researchers have found that experiments that block or knockout TREX1 allow HIV to trigger DNA sensors inducing the interferon response.2

Role of STING Pathway

When TREX1 fails to degrade DNA as it should, an accumulation of cytosolic DNA activates the STING (stimulator of interferon genes) signaling pathway. It is recognized by cGAS, allowing cGAMP, a cyclic di-nucleotide produced in the cytosol in response to double-stranded DNA (dsDNA), to bind to STING.2

Since it can control proteins like IFN- β, an inflammatory mediator, TBK1 is a key player in the initiation of inflammation. When TBK1 phosphorylates STING, it makes it easier for IRF3 to bind to it. TBK1 then phosphorylates IRF3, which then translocates to the nucleus and drives IFN-α and/or IFN-β transcription.³

The STING (stimulator of interferon genes) pathway contributes to IRF3 phosphorylation and activation, resulting in antiviral activity.

HIV

Currently, there is no cure for HIV, and if left untreated, it could lead to acquired immunodeficiency syndrome (AIDS), which increases the chances of other diseases since the immune system is highly compromised. Nowadays, there’s a combination of drugs to treat/slow HIV to the point of non-detection; however, like with other diseases, drug resistance becomes an issue after long-term use. Therefore, scientists are always searching for solutions. At present, the following classes of anti-HIV drugs that work in various ways are:

  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs)
  • Protease inhibitors (PIs)
  • Integrase inhibitors
  • Entry or fusion inhibitors

TREX1 Inhibitor Assays

With the significant role that TREX1 plays in the HIV immune response, inhibitors have been considered for therapeutic potential. Researchers have already started discovering TREX1 inhibitors to combat HIV; however, there is much to learn and precautions to consider since TREX1 have other disease implications to consider; autoimmune disorders can be the result of too little TREX1. 2 A TREX1 inhibitor could help nudge the immune system into helping fight cancer as well.

TREX1 activity assays capable of detecting enzymatic activity are ideal for screening possible inhibitors for therapeutic qualities. An assay that can test thousands of compounds at once is perfect for drug discovery and would further enhance research efforts. Currently, BellBrook Labs is working on an NIH-sponsored grant to develop a new HTS compatible assay for TREX1 inhibitors.

References

  1. Wheeler, L. A., Trifonova, R. T., Vrbanac, V., Barteneva, N. S., Liu, X., Bollman, B., … Lieberman, J. (2016). TREX1 Knockdown Induces an Interferon Response to HIV that Delays Viral Infection in Humanized Mice. Cell Reports, 15(8), 1715–1727. https://doi.org/10.1016/j.celrep.2016.04.048
  2. Junjie Qian. (2012). DISCOVERY OF SMALL-MOLECULE COMPOUNDS TARGETING TREX1 by Junjie Qian A Thesis Presented to the FACULTY OF THE USC GRADUATE SCHOOL UNIVERSITY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree MASTER OF SCIENCE (BIOCHEMISTRY AND MOLECULE BIOLOGY) http://digitallibrary.usc.edu/cdm/ref/collection/p15799coll3/id/74180
  3. Bowie, A. G. (2013). Removing the trex1 safety net: Oxidized DNA overcomes immune silencing by exonuclease TREX1. Immunity, 39(3), 423–425. https://doi.org/10.1016/j.immuni.2013.08.023
Tagged under: TREX1, TREX1 Inhibitors

What you can read next

The Power of PKM2
DDX3 inhibitors antiviral therapeutics
Can DDX3 Inhibitors Lead to the Discovery of Antiviral Therapies?
Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP